Division of Celldex Therapeutics Inc.
Latest From CuraGen Corp.
This week's company moves include the sudden departure of Celgene's COO, new CEOs at Abeona Therapeutics, Kleo Pharmaceuticals and Corvidia Therapeutics, while board appointments have been made at Neurocentrx, Hemogenyx Pharmaceuticals, Emergex Vaccines and Rezolute Inc.
Takeda is ramping up its presence in oncology, having signed a deal with antibody-drug conjugate (ADC) specialist Mersana Therapeutics via subsidiary Millennium Pharmaceuticals.
Dutch molecular diagnostics specialist Qiagen has become the latest firm to enter the next-generation genome sequencing foray, having revealed that it has acquired privately-held Intelligent Bio-Systems and hopes to launch its first next-generation sequencing (NGS) solution next year.
Two months after launching its hostile takeover bid of Illumina and having made little progress, Roche has increased its offer by 15%, to $51 per share, bringing the total transaction value to $6.7 billion. However, this still may not be enough for the Swiss drugs and diagnostics giant to bag the gene sequencing firm, the stock of which analysts have previously said could be worth around $60 per share.
Drug Discovery Tools
- Drug Discovery Tools
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Celldex Therapeutics Inc.
- Senior Management
Timothy Shannon, MD, Pres. & CEO
Sean Cassidy, VP, CFO
- Contact Info
Phone: (203) 481-1104
322 East Main St.
Branford, CT 06405
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.